Slowly releasing piperazine ferulate

A piperazine ferulic acid, sustained-release preparation technology, applied in the field of piperazine ferulic acid sustained-release preparations, can solve the problems of slight side effects, general curative effect, etc., and achieve the effect of improving clinical indicators, significant curative effect, and improving curative effect

Inactive Publication Date: 2003-10-08
成都亨达药业有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The existing Baoshenkang for the treatment of nephropathy mainly contains piperazine ferulic acid. Its peak blood absorption time is 30 minu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Tablets (also capsules) made by methods known in the pharmaceutical industry contain the following components by weight percentage:

[0028] Piperazine Ferulate 66.50%

[0029] METHOCEL K 4 (Methocel K 4 MCR) 30%

[0030] 3% hydroxypropyl methylcellulose ethanol solution (3% HPMC ethanol solution) 3%

[0031] Magnesium Stearate 0.5%

[0032] METHOCEL K 4 The hydrophilic polymer is the skeleton material in the preparation, which swells with water or digestive juice to form a gel barrier to control the diffusion of piperazine ferulate and achieve the purpose of sustained release.

Embodiment 2

[0034] The present embodiment 2 tablet that adopts the known method of pharmaceutical industry to make contains following component by weight percentage:

[0035] Piperazine Ferulate 70%

[0036] Carbopol 29.9%

[0037] Magnesium Stearate 0.1%

[0038] Hydrophilic polymer carboxyvinyl (carbomer) is the skeleton material, which swells with water or digestive juice to form a gel barrier to control the diffusion of piperazine ferulic acid and achieve the purpose of slow release.

Embodiment 3

[0040] The present embodiment 3 tablet that adopts the known method of pharmaceutical industry to make contains following component by weight percentage:

[0041] Piperazine Ferulate 58%

[0042] Ethyl Cellulose with Stearic Acid 30%

[0043] Ethylcellulose absolute ethanol solution 10%

[0044] Magnesium Stearate 2%

[0045] Stearic acid, a bioerodible material, can be gradually eroded in the body so that the main drug is gradually released to play a sustained release role. Ethyl cellulose is a non-erodible skeleton material, which is excreted after the drug is released.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slowly releasing piperazine ferulate preparation for treating acute or chronic glomerulus disease, nephrosis syndrome, renal failure, autoimmune nephrosis, hematopathy and cardiovascular disease contains piperazine ferulate (40-70 wt.%), auxiliary material playing the role of slow release (10-30 wt.%) and others (the rest). Said auxiliary material may be hydroxypropyl methylcellulose and/or ethylcellulose and/or polyacrylic resins and/or polyhydroxyethenes. Its advantages include long active blood concentration period (24 hr), high curative effect and low reaction.

Description

Technical field: [0001] The invention relates to a sustained-release preparation of piperazine ferulate mainly used for treating acute and chronic glomerular diseases, nephrotic syndrome, renal failure, autoimmune nephropathy, hemagglutination kidney disease and cardiovascular disease. Background technique: [0002] The existing Baoshenkang for the treatment of nephropathy mainly contains piperazine ferulic acid. Its peak blood absorption time after oral administration is 30 minutes, its distribution half-life is 27 minutes, and its elimination half-life is 5.5 hours. Invention content: [0003] In view of the above reasons, the object of the present invention is to provide a sustained-release preparation of piperazine ferulate that maintains effective blood drug concentration within 24 hours, improves curative effect and reduces side effects. [0004] The purpose of the present invention is achieved like this: [0005] Preparation of the present invention contains follow...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/22A61K9/28A61K9/48A61K31/495A61P13/12
Inventor 陆彬唐胜英
Owner 成都亨达药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap